Search
for
Sort by
Research 31–60 of 1000+
- PAK4 signaling in health and disease: defining the PAK4–CREB axis
- Prostatakarzinom
- Hormone Blocking Anticancer Drugs
- 5α‐Reductase Inhibitors
- Therapeutic Strategies to Target the Androgen Receptor
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways
- Molecular mechanisms of androgen receptor functions
- Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice
- Androgen receptors and their biology
- Imaging prostate cancer (PCa) with [<sup>99m</sup> Tc(CO)<sub>3</sub> ]finasteride dithiocarbamate
- Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele
- The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
- Redefining hormone resistance in prostate cancer
- Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer
- Prostate cancer update: 2007
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
- Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
- The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
- Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer
- Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
- Male pattern baldness and the risk of prostate cancer
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer
- Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
- 5α- Reductase Inhibitors in Prostate Cancer: An Overview
- 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia
- Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression